BACKGROUND: Treatment of pediatric lymphocyte-predominant Hodgkin lymphoma (LPHL) is controversial but has typically consisted of both chemotherapy and radiation. Radiation therapy is associated with potential late effects in children and adolescents. We examined the impact of radiation therapy on long-term outcome of patients with LPHL treated on CCG-5942, a large pediatric cooperative group study of Hodgkin lymphoma (HL). PROCEDURE: Eighty-two patients with LPHL were registered on CCG-5942. Fifty-two patients (63%) received chemotherapy alone; 29 patients (35%) received chemotherapy followed by involved-field radiation therapy (IFRT). RESULTS: The median follow-up of the LPHL patients is 7.7 years; 63 patients (77%) have >5 years of follow-up. The 5-year event-free survival (EFS) and overall survival (OS) were 97% and 100%. Two relapses occurred, both in patients who did not receive IFRT. There were no significant differences in EFS or OS between patients who received or did not receive IFRT. CONCLUSIONS: This subset analysis demonstrates the chemosensitivity of pediatric LPHL. Patients who had a complete response to chemotherapy had an excellent EFS and OS without the addition of radiotherapy.
BACKGROUND: Treatment of pediatric lymphocyte-predominant Hodgkin lymphoma (LPHL) is controversial but has typically consisted of both chemotherapy and radiation. Radiation therapy is associated with potential late effects in children and adolescents. We examined the impact of radiation therapy on long-term outcome of patients with LPHL treated on CCG-5942, a large pediatric cooperative group study of Hodgkin lymphoma (HL). PROCEDURE: Eighty-two patients with LPHL were registered on CCG-5942. Fifty-two patients (63%) received chemotherapy alone; 29 patients (35%) received chemotherapy followed by involved-field radiation therapy (IFRT). RESULTS: The median follow-up of the LPHL patients is 7.7 years; 63 patients (77%) have >5 years of follow-up. The 5-year event-free survival (EFS) and overall survival (OS) were 97% and 100%. Two relapses occurred, both in patients who did not receive IFRT. There were no significant differences in EFS or OS between patients who received or did not receive IFRT. CONCLUSIONS: This subset analysis demonstrates the chemosensitivity of pediatric LPHL. Patients who had a complete response to chemotherapy had an excellent EFS and OS without the addition of radiotherapy.
Authors: A Braeuninger; R Küppers; J G Strickler; H H Wacker; K Rajewsky; M L Hansmann Journal: Proc Natl Acad Sci U S A Date: 1997-08-19 Impact factor: 11.205
Authors: G Karayalcin; F G Behm; P W Gieser; F Kung; M Weiner; C K Tebbi; C Ferree; R Marcus; L Constine; N P Mendenhall; A Chauvenet; S B Murphy Journal: Med Pediatr Oncol Date: 1997-12
Authors: T Marafioti; M Hummel; I Anagnostopoulos; H D Foss; B Falini; G Delsol; P G Isaacson; S Pileri; H Stein Journal: N Engl J Med Date: 1997-08-14 Impact factor: 91.245
Authors: S Bodis; M D Kraus; G Pinkus; B Silver; M E Kadin; G P Canellos; L N Shulman; N J Tarbell; P M Mauch Journal: J Clin Oncol Date: 1997-09 Impact factor: 44.544
Authors: V Diehl; M Sextro; J Franklin; M L Hansmann; N Harris; E Jaffe; S Poppema; M Harris; K Franssila; J van Krieken; T Marafioti; I Anagnostopoulos; H Stein Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: S Bhatia; L L Robison; O Oberlin; M Greenberg; G Bunin; F Fossati-Bellani; A T Meadows Journal: N Engl J Med Date: 1996-03-21 Impact factor: 91.245
Authors: Lianna J Marks; Qinglin Pei; Rizvan Bush; Allen Buxton; Burton Appel; Kara M Kelly; Cindy L Schwartz; Debra L Friedman Journal: Pediatr Blood Cancer Date: 2018-09-14 Impact factor: 3.167
Authors: Angie Mae Rodday; Theresa Hahn; Anita J Kumar; Peter K Lindenauer; Jonathan W Friedberg; Andrew M Evens; Susan K Parsons Journal: Br J Haematol Date: 2020-02-23 Impact factor: 6.998
Authors: Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz Journal: J Clin Oncol Date: 2016-05-16 Impact factor: 44.544
Authors: Sarah A Milgrom; Jihyun Kim; Alin Chirindel; Jongho Kim; Qinglin Pei; Lu Chen; Allen Buxton; Sandy Kessel; Jeffrey Leal; Kathleen M McCarten; Bradford S Hoppe; Suzanne L Wolden; Cindy L Schwartz; Debra L Friedman; Kara M Kelly; Steve Y Cho Journal: Pediatr Blood Cancer Date: 2021-07-10 Impact factor: 3.838